These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1196239)

  • 21. [Practice guideline--peripheral arterial occlusive disease. Drug Committee of the German Medical Association].
    Z Arztl Fortbild Qualitatssich; 1997 Jul; 91(4):385-7. PubMed ID: 9340210
    [No Abstract]   [Full Text] [Related]  

  • 22. Trials of 3,7-dimethyl-1-(5-oxohexyl) xanthine (BL 191) in double-blind tests.
    Buckert D; Harwart D
    Farmaco Prat; 1976 May; 31(5):264-74. PubMed ID: 773679
    [No Abstract]   [Full Text] [Related]  

  • 23. [Guidelines for the evaluation of the therapeutic effects of peripheral vasoactive drugs in arterial occlusive disease].
    Adank K; Barras JP; Biland L; Bollinger A; Galeazzi R; Kämpf R; Mirimanoff P; Schelling JL; Widmer LK
    Vasa; 1981; 10(4):337-41. PubMed ID: 7032111
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical trials of a vasoactive drug in arteriopathies of the limbs].
    Courbier R; Jausseran JM; Reggi M
    Sem Hop Ther; 1977 Jan; 53(1):47-51. PubMed ID: 854750
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparison of 2 effective doses of Fludilat in peripheral vascular disorders in a double-blind trial].
    König FK
    Med Welt; 1973 Sep; 24(39):1490-2. PubMed ID: 4588974
    [No Abstract]   [Full Text] [Related]  

  • 26. Vasodilators for arterial insufficiency.
    Naide D
    Am Fam Physician; 1980 Jul; 22(1):128-9. PubMed ID: 7386349
    [No Abstract]   [Full Text] [Related]  

  • 27. [Evaluation of delayed-action Tebonin with the study of muscle flow, using xenon 133].
    Matteoni R; Reale R; Lauri D; Sirolli C; Tata MV
    Minerva Cardioangiol; 1973 Apr; 21(4):264-71. PubMed ID: 4710123
    [No Abstract]   [Full Text] [Related]  

  • 28. [Prostaglandins including prostacyclin in the treatment of peripheral arterial occlusive disorders].
    Alexander K
    Internist (Berl); 1989 Jul; 30(7):429-39. PubMed ID: 2670810
    [No Abstract]   [Full Text] [Related]  

  • 29. [Results of a clinical study on the vasodilator 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (BL 191)].
    Lehrach F; Müller R
    Arzneimittelforschung; 1971 Aug; 21(8):1171-4. PubMed ID: 5110012
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].
    Sunder-Plassmann L; Gandolfo AM; Utz C
    MMW Munch Med Wochenschr; 1984 Mar; 126(9):247-8. PubMed ID: 6425678
    [No Abstract]   [Full Text] [Related]  

  • 31. [New data on vasoactive drug. Patients with peripheral arterial occlusive disease walk twice as long].
    MMW Fortschr Med; 2002 May; 144(21):54. PubMed ID: 12134429
    [No Abstract]   [Full Text] [Related]  

  • 32. [Parameters for the measurement of long-term effects of an orally administered drug in organic and functional circulatory disorders. Preliminary communication].
    Schuster CJ; von Ungern-Sternberg AF
    ZFA (Stuttgart); 1976 Jan; 52(2):105-10. PubMed ID: 817527
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pharmacologic properties and indications of modern vasodilator agents. 2: Indications and side effects of vasodilator agents].
    Langnickel R; Bluth R
    Z Arztl Fortbild (Jena); 1985; 79(20):867-73. PubMed ID: 3936287
    [No Abstract]   [Full Text] [Related]  

  • 34. [Intra-arterial administration of penicillin and vasodilating agents in occlusive diseases of the peripheral arteries].
    Hubl S; Wesolowski J
    Pol Tyg Lek; 1973 Jul; 28(30):1150-1. PubMed ID: 4732712
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of peripheral arterial diseases].
    Mikita J
    Orv Hetil; 2005 May; 146(22):1209-11. PubMed ID: 15997667
    [No Abstract]   [Full Text] [Related]  

  • 36. [Methods for studying vasoactive drugs in arteriopathy of the leg and chronic venous insufficiency].
    Franco A; Carpentier P
    Arch Mal Coeur Vaiss; 1990 Mar; 83 Spec No 2():79-82. PubMed ID: 2111691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experiences with the new vasotherapeutic drug Trental in dermatology].
    Herger R
    Fortschr Med; 1972 Aug; 90(24):865-72. PubMed ID: 4639351
    [No Abstract]   [Full Text] [Related]  

  • 38. [What is the status of vasoactive drugs? Early stages of arterial occlusive disease in general practice--positive series list, 3].
    Schmidt K
    Fortschr Med; 1995 Apr; 113(12):41-2. PubMed ID: 7789936
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of trophic ulcers of the lower extremities with Trental-400].
    Koshkin VM; Bogdanets LI; Makarova LD
    Khirurgiia (Mosk); 1996; (1):49-51. PubMed ID: 8683922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Compensatory degree of arterial obstruction and effect of intravenously administered vasoactive drugs].
    Bollinger A; Lüthy E
    Schweiz Med Wochenschr; 1967 Sep; 97(37):1220-5. PubMed ID: 5593064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.